National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Stiripentol (Diacomit®) for use in conjunction with clobazam and valproate as adjunctive therapy of
refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy
(SMEI, Dravet’s syndrome) whose seizures are not adequately controlled with clobazam and

NCPE Assessment Process Ongoing
Rapid review received 06/07/2017
Rapid review completed 10/08/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended
Full pharmacoeconomic assessment commissioned by HSE 04/09/2017
Pre-submission consultation with Applicant 15/01/2018
Submission received from Applicant 06/07/2018
Preliminary review sent to Applicant 19/10/2018
NCPE assessment re-commenced 21/12/2018
Factual accuracy sent to Applicant 14/03/2019
NCPE assessment re-commenced 29/03/2019
Current Status NCPE assessment ongoing